Metolazone Add-On Therapy in Heart Failure: A Cohort Study from Persian Registry of Cardiovascular Disease/Heart Failure (PROVE/HF).

Farzad Rahimi Mehrbod Vakhshoori Maryam Heidarpour Fatemeh Nouri Kiyan Heshmat-Ghahdarijani Mohammad Fakhrolmobasheri Davood Shafie

Published in: Critical care research and practice (2021)

Our findings revealed that adding metolazone in patients with furosemide resistance is not associated with higher morbidity and mortality. Therefore, usage of these two therapeutic agents could be a helpful strategy for severe HF patients.

Keyphrases

heart failure
cardiovascular disease
acute heart failure
end stage renal disease
newly diagnosed
left ventricular
type diabetes
peritoneal dialysis
prognostic factors
atrial fibrillation
cardiac resynchronization therapy
metabolic syndrome
mesenchymal stem cells